Active ingredient: Amphetamine Aspartate; Amphetamine Sulfate; 
Dextroamphetamine Saccharate; Dextroamphetamine Sulfate 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: 

______________________________________________________________________________ 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: Please refer to the Amantadine Hydrochloride Tablet Draft 
Guidance for additional information regarding fed studies. 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): D-amphetamine and l-amphetamine, 
measured separately in plasma 

 

Bioequivalence based on (90% CI): D-amphetamine and l-amphetamine 

 

Waiver request of in vivo testing: (1. 25 mg; 1.25 mg; 1.25mg; 1.25 mg), (1.875 mg, 1.875 mg; 
1.875 mg: 1.875 mg), (2.5 mg, 2.5 mg. 2.5 mg, 2.5 mg), (3.125 mg, 3.125 mg, 3.125 mg, 3.125 mg), 
(3.75 mg, 3.75 mg, 3.75 mg, 3.75 mg), (5 mg, 5 mg, 5 mg, 5 mg) strengths based on (i) acceptable 
bioequivalence studies on the (7.5 mg, 7.5 mg, 7.5 mg, 7.5 mg) strength, (ii) acceptable dissolution 
testing across all strengths, and (iii) proportional similarity in the formulations across all strengths. 

 

Dissolution test method and sampling times: 

Please note that a Dissolution Methods Database is available to the public at the OGD website at 
http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for 
this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of 
all strengths of the test and reference products. Specifications will be determined upon review of the 
application. 


